IRIS
LAURIA, ROSSELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.328
AS - Asia 2.326
EU - Europa 1.954
SA - Sud America 271
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 6.940
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.231
SG - Singapore 962
RU - Federazione Russa 809
VN - Vietnam 561
IT - Italia 485
CN - Cina 432
BR - Brasile 207
HK - Hong Kong 167
DE - Germania 164
FR - Francia 112
NL - Olanda 98
FI - Finlandia 80
UA - Ucraina 70
CA - Canada 58
IN - India 46
GB - Regno Unito 44
IE - Irlanda 27
JP - Giappone 26
BD - Bangladesh 24
AR - Argentina 22
ZA - Sudafrica 22
MX - Messico 21
SE - Svezia 15
EC - Ecuador 14
PH - Filippine 14
CI - Costa d'Avorio 13
IQ - Iraq 13
PL - Polonia 12
ES - Italia 11
PK - Pakistan 11
KR - Corea 10
TH - Thailandia 10
CO - Colombia 9
VE - Venezuela 8
AT - Austria 7
TW - Taiwan 7
ID - Indonesia 6
UZ - Uzbekistan 6
JM - Giamaica 5
LT - Lituania 4
MY - Malesia 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
DO - Repubblica Dominicana 3
EG - Egitto 3
HN - Honduras 3
IL - Israele 3
PS - Palestinian Territory 3
PY - Paraguay 3
RO - Romania 3
TR - Turchia 3
BZ - Belize 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
EU - Europa 2
GE - Georgia 2
KE - Kenya 2
LK - Sri Lanka 2
MA - Marocco 2
NP - Nepal 2
RS - Serbia 2
SI - Slovenia 2
TN - Tunisia 2
VC - Saint Vincent e Grenadine 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
BF - Burkina Faso 1
CG - Congo 1
CV - Capo Verde 1
DK - Danimarca 1
GA - Gabon 1
GT - Guatemala 1
IR - Iran 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
LV - Lettonia 1
LY - Libia 1
ME - Montenegro 1
MK - Macedonia 1
MN - Mongolia 1
MQ - Martinica 1
MT - Malta 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
SN - Senegal 1
TJ - Tagikistan 1
TZ - Tanzania 1
ZW - Zimbabwe 1
Totale 6.940
Salva come PNG Salva come JPEG
Città #
Singapore 473
San Jose 358
Chandler 242
Ashburn 191
Moscow 189
Beijing 164
Ho Chi Minh City 159
Hong Kong 153
Hanoi 119
Amsterdam 91
Napoli 86
Santa Clara 80
Los Angeles 64
Millbury 59
Jacksonville 48
The Dalles 47
Dallas 46
Munich 45
Naples 44
Lauterbourg 43
New York 41
Princeton 40
Nanjing 34
Buffalo 31
Da Nang 26
Haiphong 26
São Paulo 25
Dong Ket 24
Turku 23
Helsinki 22
Tokyo 22
Wilmington 20
Des Moines 19
Toronto 19
Orem 17
Council Bluffs 16
Montreal 16
Pune 16
Boston 15
Johannesburg 14
Tianjin 14
Frankfurt am Main 13
Milan 13
Redondo Beach 13
Seattle 13
Hefei 12
Ottawa 11
Atlanta 10
London 10
Warsaw 10
Chicago 9
Hải Dương 9
Lawrence 9
Mexico City 9
Rome 9
Shenyang 9
Stockholm 9
Brooklyn 8
Denver 8
Falkenstein 8
Falls Church 8
Houston 8
Nanchang 8
Poplar 8
Belo Horizonte 7
Charlotte 7
Guayaquil 7
Jiaxing 7
Ninh Bình 7
Nuremberg 7
Phoenix 7
Redwood City 7
Rio de Janeiro 7
Rozzano 7
San Francisco 7
Ann Arbor 6
Casoria 6
Manchester 6
Porto Alegre 6
Shanghai 6
Tashkent 6
Augusta 5
Biên Hòa 5
Borgomanero 5
Can Tho 5
Changsha 5
Chennai 5
Dublin 5
Hangzhou 5
Jinan 5
Kingston 5
Leawood 5
Mumbai 5
Nola 5
Quito 5
Salerno 5
Thái Nguyên 5
Washington 5
Baghdad 4
Bangkok 4
Totale 3.611
Salva come PNG Salva come JPEG
Nome #
Manuale di Oncologia Clinica 234
null 223
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine 184
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 182
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 180
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 178
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 173
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 164
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 156
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 155
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 153
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 152
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 152
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 151
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 150
Tumor characteristics and prognosis in familial breast cancer 148
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 146
Tumor segmentation analysis at different post-contrast time points: A possible source of variability of quantitative DCE-MRI parameters in locally advanced breast cancer 146
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 144
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 144
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 142
Changing presentation in non Hodgkin lymphoma". 141
Decision making in borderline ovarian tumors: report of a rare case of mesosigma psammocarcinoma 136
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 136
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 134
Chlorambucil, Vincristine and Cytarabine (COA) treatment of low grade lymphomas 133
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study 132
Core curriculum. Oncologia clinica 131
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. 130
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 130
Partial deficiency of adrenal 11-hydroxylase: A possible cause of primary hypertension 126
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 125
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 122
Tailored therapy for aggressive non-Hodgkin’s lymphoma: results of a phase II study with a long-term follow-up. 121
'Primary Bone Lymphoma". 121
CAVBP-DEP Altemative Chemotherapy for the treatment of intermediate and high grade non Hodgkin lymphoma: final results of a pilot study. 121
Core curriculum. Oncologia clinica 121
Advanced and Locally unresectable gastric carcinoma: five years of survival with good quality of life. 119
Capitolo 15: i Tumori Ginecologici 117
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 115
: Low dose dopamine induces early recovery of recombinant Interleukin-2 impaired renal function. 112
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 111
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy. 110
Maintenance therapy with recombinant Interferon Alpha-2b (IFN) in prognostically in prognastically unfavourable aggressive non-Hodgkin’s lymphomas. 107
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. 106
Bone involvement by adenocarcinoma of the uterine cervix: a rare entity 106
Comparison of Tropisetron (ICS 205-930) with alizapride plus dexamethasone in the prevention of emesis induced by repeated cisplatin administration. 105
Salvage chemotherapy for non Hodgldn's lymphoma of unfavorable histology with a combination of CCNU and Vinblastine. 98
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. 92
First-line systemic therapy for metastatic breast cancer and management of pleural effusion. 78
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety 71
null 67
Totale 7.031
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.784
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022342 8 1 7 5 3 13 6 9 26 40 111 113
2022/2023523 57 65 18 42 57 54 3 39 74 92 16 6
2023/2024284 11 52 32 22 17 47 5 29 4 5 48 12
2024/20251.563 63 42 13 20 66 80 137 117 89 152 669 115
2025/20263.303 317 171 341 317 544 165 475 149 397 289 76 62
2026/202769 69 0 0 0 0 0 0 0 0 0 0 0
Totale 7.031